FR EA

Extract to table

Pull the structured facts out of a document: parties, dates, amounts, obligations.

Extract to table / remaining-issues-resolution-memo.docx
remaining-issues-resolution-memo.docx · 1018-00004

Parties

HARKNESS LLP
Penterra Pharmaceuticals Corp
Agreement Between Penterra Pharmaceuticals Corp
Callahan LLP
Penterra SA

Dates

June 20, 2023
June 16, 2023
June 19, 2023
June 23, 2023
June 28, 2023
July 18, 2023
August 14, 2023
March 20, 2023
April 7, 2023
April 28, 2023

Amounts

$80,000,000
$500,000
$15,000,000
$13,000
$5,000,000
$20,000,000
$25,000,000
$75,000,000
$40,000
$3,333.33

Obligations

This approach provides Veridian with full compensation for the coordination services it is required to provide during the wind-down while avoiding overpayment for periods after the wind-down concludes
Invoices for such work must be submitted in accordance with the standard payment procedures set forth in the MCTA and are subject to the same Net 45 payment terms
Veridian and its participating sites must continue to submit invoices in the format and through the channels specified in the MCTA during the wind-down period
This gap was identified as a critical open item in the June 10, 2023 memorandum because the treatment of subjects who may be deriving clinical benefit from penterafenib raises significant ethical, regulatory, and practical concerns that must be addressed in the governing agreement
During the extended access period, the site investigator must actively pursue transition of the subject to commercially available therapy (including approved alternative therapies for advanced HCC) or enrollment in another clinical trial, and must document these efforts in the subject's medical record
Site investigators must report any SAEs to Penterra within twenty-four (24) hours of the site's becoming aware of the event, consistent with 21 C